Fingerprint
Dive into the research topics of 'A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically